⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte Announces Additional FDA Approval of Opzelura ® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
businesswire.com
INCY
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
businesswire.com
INCY